Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metformin/saxagliptin immediate release - AstraZeneca

Next Previous
Drug Profile

Metformin/saxagliptin immediate release - AstraZeneca

Alternative Names: Kombiglyze; Komboglyze; Metformin immediate release/saxagliptin; Metformin IR/saxagliptin; Onglyza/metformin IR FDC; Saxagliptin/metformin IR

Latest Information Update: 28 Jul 2019

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer AstraZeneca
  • Class Adamantanes; Antihyperglycaemics; Biguanides; Dipeptides; Insulin sensitisers; Nitriles; Organic bridged compounds; Piperidines; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Dipeptidyl peptidase 4 inhibitors; Gluconeogenesis inhibitors; Glucose modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 28 Jul 2019 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in USA (PO, Tablet)
  • 30 Jan 2019 Chemical structure information added
  • 11 Jul 2017 Saxagliptin/metformin immediate release is still in Preregistration for Type-2 diabetes mellitus in China (AstraZeneca pipeline, July 2017)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top